Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations

JD Ravid, O Leiva, VC Chitalia - Cells, 2022 - mdpi.com
Acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection continues to be a
worldwide public health crisis. Among the several severe manifestations of this disease …

[HTML][HTML] COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy

M Khaledi, F Sameni, S Yahyazade… - Frontiers in …, 2022 - frontiersin.org
Recent evidence proposed that the severity of Coronavirus disease 2019 (COVID-19)
patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18 …

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection

F Solimani, K Meier, K Ghoreschi - European journal of …, 2021 - Wiley Online Library
Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects
of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial …

Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19

W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020 - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia

Y Tanaka - Inflammation and Regeneration, 2023 - Springer
Background In inflamed tissue, immune cells are accumulated, and various intercellular
signals are involved in the pathogenesis. Janus kinases (JAKs) are typical tyrosine kinases …

Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets

K Sriram, PA Insel - Physiological reviews, 2021 - journals.physiology.org
Evolving information has identified disease mechanisms and dysregulation of host biology
that might be targeted therapeutically in coronavirus disease 2019 (COVID-19). Thrombosis …

JAK-STAT pathway inhibition and their implications in COVID-19 therapy

S Satarker, AA Tom, RA Shaji, A Alosious… - Postgraduate …, 2021 - Taylor & Francis
As the incidence of COVID-19 increases with time, more and more efforts are made to pave
a way out for the therapeutic strategies to deal with the disease progression. Inflammation …

Pathophysiological mechanisms of thrombosis in acute and long COVID-19

H Jing, X Wu, M Xiang, L Liu, VA Novakovic… - Frontiers in …, 2022 - frontiersin.org
COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …

The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy

MR Khezri, R Varzandeh… - Cellular & Molecular …, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19), which is caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), is associated with a high mortality rate …

Coagulation disorders in COVID-19: role of toll-like receptors

I Biswas, GA Khan - Journal of Inflammation Research, 2020 - Taylor & Francis
Abstract Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the world.
The range of the disease is broad but among hospitalized patients with COVID-19 are …